Bristol-Myers Squibb Company

- The company plans to take on additional debt in 2024 to finance the acquisitions of Karuna and RayzeBio. - Despite the increased debt, the company has a strong financial position with $12.6 billion in cash and marketable securities as of the latest quarter. - The company intends to generate strong cash flow (e.g., $4.3 billion in Q4) to pay down approximately $10 billion of debt over the next two years and improve leverage. - There is no mention of planned equity fundraising in the provided sections. - The company remains focused on financial discipline and operational efficiencies while investing in growth and managing its capital structure prudently.

- The company has executed several deals toward the end of last year and is focused on integrating those currently. - Business development remains a priority, with ongoing interest in bolt-on acquisitions, partnerships, and licensing deals that make strategic and financial sense. - Additional debt financing planned this year to fund acquisitions of Karuna and RayzeBio. - Plan to repay approximately $10 billion of debt over the next two years to improve leverage. - Capital allocation strategy emphasizes maintaining strong cash flow, investing in growth, and operational efficiencies. - Continued investment in expanding product launches and strengthening the commercial presence (e.g., Breyanzi commercialization, new product launches like KarXT). - Investment in supply chain enhancements, such as strengthening vector supply capacity for Breyanzi. - Ongoing discussions with regulatory authorities and potential additional trials/trials expansions indicate sustained R&D investment. Overall, strategic investments focus on acquisitions, R&D, and commercial infrastructure to support growth.

- 2024 revenue guidance projects a low single-digit percentage increase on an underlying basis, reflecting confidence in growing momentum of the growth portfolio. - Growth portfolio expected to drive sales increase, led by products like Opdivo and newly launched medicines. - Opdivo growth pace anticipated to be more modest than 2023 but may accelerate in the second half of 2024 with new indications. - Strong sales growth forecast for Eliquis, especially in the U.S., despite generic pressures internationally. - Sotyktu expected to build prescription volume steadily through 2024, aiming to double paid prescriptions to ~20,000 in Q4 2024. - Reblozyl sales growth expected to continue, fueled by first-line MDS launch in the U.S. and approvals in Japan and Europe. - Breyanzi sales projected to grow strongly starting Q2 2024, supported by expanded indications and improved supply capacity. - Zeposia sales anticipated to maintain growth momentum despite typical Q1 seasonal impacts. - Overall operational efficiencies and pipeline advancements to support sustainable growth longer-term, targeting top-tier growth by late decade.

- Bristol Myers Squibb expects reported revenue growth in a low single-digit range in 2024, driven by momentum in the growth portfolio and stable legacy portfolio performance. - Gross margin is projected at approximately 74% for 2024, reflecting changes in sales mix and absence of prior hedging gains. - Operating expenses (MS&A) are anticipated to increase in the low single-digit range due to additional costs from Mirati acquisition and cost reallocations. - Operating Income & Expense (OI&E) is expected to be about $250 million income, influenced by PD-1 royalty streams and Mirati acquisition financing costs. - The effective tax rate is projected at roughly 17.5%, accounting for nonrecurrence of prior benefits and new tax provisions. - Non-GAAP earnings per share (EPS) guidance for 2024 is between $7.10 and $7.40, excluding dilutive impacts from pending acquisitions. - Karuna and RayzeBio acquisitions are expected to be dilutive to EPS by approximately $0.30 and $0.13 respectively in 2024.

- Sotyktu: Orderbook/progress includes moving patients from Bridge programs to commercial products; Q4 prescriptions expected around 20,000, roughly double earlier levels, with volume momentum continuing into Q1 2024 and beyond. - Reblozyl: Strong sales momentum with expanding first-line MDS use; approved internationally (Japan, expected EU approval in H1 2024), implying ongoing order growth. - Other products (e.g., Opdualag, Breyanzi, Camzyos): Continuing launches and expanding indications indicate growing demand and order volumes. - Inventory impact: Some favorable wholesaler stocking noted (Opdivo, Opdualag) influencing near-term orderbook. - Overall sales growth and access improvements point to an expanding orderbook, with continuing negotiations with payers expected to further enhance commercial access and demand during 2024.